A Trial of SHR-1703 in Healthy Adults

Summary

SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in Healthy subjects. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose SHR-1703 administered subcutaneously in Chinese healthy subjects.

Timeline

Start

2020-08-04

Primary completion

2021-09-21

Completion

2021-09-21

Publications

• Yang L, Fang Y, Luo Y, Fu M, Shen K, Luo Z. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study. Expert Opin Investig Drugs. 2024 Jul;33(7):741-752. doi: 10.1080/13543784.2024.2361065. Epub 2024 Jun 3.

Drugs

Indications